Novartis AG (NYSE:NVS)‘s stock had its “neutral” rating reaffirmed by stock analysts at J P Morgan Chase & Co in a report issued on Tuesday, October 31st.
Several other research analysts also recently commented on the company. Zacks Investment Research upgraded Novartis AG from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. Barclays PLC downgraded Novartis AG from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, October 25th. Leerink Swann boosted their price target on Novartis AG from $89.00 to $91.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. BidaskClub upgraded Novartis AG from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Finally, Cowen and Company set a $90.00 price target on Novartis AG and gave the company a “hold” rating in a research note on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $85.32.
Novartis AG (NVS) traded up $0.96 during trading hours on Tuesday, hitting $83.98. The company’s stock had a trading volume of 1,545,668 shares, compared to its average volume of 2,313,796. The firm has a market cap of $198,662.67, a price-to-earnings ratio of 17.68, a price-to-earnings-growth ratio of 2.68 and a beta of 0.72. Novartis AG has a 52-week low of $66.93 and a 52-week high of $86.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81.
Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.25 by $0.04. Novartis AG had a return on equity of 15.77% and a net margin of 13.73%. The company had revenue of $12.41 billion during the quarter, compared to the consensus estimate of $12.21 billion. During the same period in the previous year, the company posted $1.23 EPS. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year. equities research analysts forecast that Novartis AG will post 4.75 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by BBNS and is owned by of BBNS. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/novartis-ags-nvs-neutral-rating-reiterated-at-j-p-morgan-chase-co/1746323.html.
Several institutional investors have recently bought and sold shares of NVS. Alliancebernstein L.P. raised its holdings in shares of Novartis AG by 34.4% during the 1st quarter. Alliancebernstein L.P. now owns 55,021 shares of the company’s stock worth $4,086,000 after buying an additional 14,081 shares in the last quarter. Schafer Cullen Capital Management Inc. raised its holdings in shares of Novartis AG by 9.1% during the 1st quarter. Schafer Cullen Capital Management Inc. now owns 2,547,314 shares of the company’s stock worth $189,189,000 after buying an additional 212,023 shares in the last quarter. Analyst IMS Investment Management Services Ltd. increased its holdings in Novartis AG by 0.7% in the 1st quarter. Analyst IMS Investment Management Services Ltd. now owns 86,058 shares of the company’s stock worth $6,400,000 after purchasing an additional 606 shares in the last quarter. BB&T Securities LLC increased its holdings in Novartis AG by 17.6% in the 1st quarter. BB&T Securities LLC now owns 694,786 shares of the company’s stock worth $51,601,000 after purchasing an additional 104,113 shares in the last quarter. Finally, ZWJ Investment Counsel Inc. acquired a new position in Novartis AG in the 1st quarter worth about $237,000. 10.74% of the stock is owned by institutional investors.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with our FREE daily email newsletter.